Cyb5r3 activation rescues secondary failure to sulfonylurea but not β-cell dedifferentiation

Area of Science:

• Endocrinology
• Molecular Biology
• Metabolic Diseases

Background:

• Diabetes mellitus involves insulin resistance and beta-cell failure, characterized by impaired insulin secretion and dedifferentiation.
• Sulfonylurea (SU) drugs improve insulin secretion but often lead to secondary failure.
• The link between SU secondary failure and beta-cell dedifferentiation remains unclear.

Purpose of the Study:

• To investigate the association between SU secondary failure and beta-cell dedifferentiation.
• To explore the role of oxidoreductase Cyb5r3 in SU failure and beta-cell function.
• To determine if Cyb5r3 activation can mitigate SU secondary failure and beta-cell dedifferentiation.

Main Methods:

• Utilized a mouse model of SU secondary failure.
• Examined beta-cell dedifferentiation in Cyb5r3 knockout mice under chronic SU administration, high-fat diet, and aging.
• Assessed the effect of a Cyb5r3 activator on insulin secretion and beta-cell dedifferentiation.

Main Results:

• SU secondary failure is associated with partial beta-cell dedifferentiation.
• Cyb5r3 knockout mice exhibited exacerbated beta-cell dedifferentiation and glucose intolerance.
• Cyb5r3 activator improved insulin secretion impaired by chronic SU treatment, but did not reverse beta-cell dedifferentiation.

Conclusions:

• Chronic SU administration contributes to the progression of beta-cell dedifferentiation.
• Cyb5r3 plays a role in mediating SU failure, but its activation does not restore dedifferentiated beta-cells.
• Cyb5r3 activation can reverse SU secondary failure by improving insulin secretion, independent of reversing beta-cell dedifferentiation.